EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway

被引:31
|
作者
Lai, Senyan [1 ]
Wang, Guihua [1 ]
Cao, Xiaonian [1 ]
Li, Zhaoming [1 ]
Hu, Junbo [1 ]
Wang, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Canc Res Inst, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China
基金
中国国家自然科学基金;
关键词
NSCLC; EMP-1; gene; PI3K/AKT pathway; tumorigenesis; GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; EPITHELIAL MEMBRANE PROTEIN-1; ACQUIRED-RESISTANCE; GEFITINIB RESISTANCE; KINASE INHIBITORS; T790M MUTATIONS; GENE; ERLOTINIB; ADENOCARCINOMAS;
D O I
10.1007/s11596-012-1043-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study examined the role of EMP-1 in tumorigenesis of non-small cell lung carcinoma (NSCLC) and the possible mechanism. Specimens were collected from 28 patients with benign lung diseases and 28 with NSCLC, and immunohistochemically detected to evaluate the correlation of EMP-1 expression to the clinical features of NSCLC. Recombinant adenovirus was constructed to over-express EMP-1 and then infect PC9 cells. Cell proliferation was measured by Ki67 staining. Western blotting was performed to examine the effect of EMP-1 on the PI3K/AKT signaling. Moreover, tumor xenografts were established by subcutaneous injection of PC9 cell suspension (about 5x10(7)/mL in 100 mu L of PBS) into the right hind limbs of athymic nude mice. The results showed EMP-1 was significantly up-regulated in NSCLC patients as compared with those with benign lung diseases. Over-expression of EMP-1 promoted proliferation of PC9 cells, which coincided with the activation of the PI3K/AKT pathway. EMP-1 promoted the growth of xenografts of PC9 cells in athymic nude mice. It was concluded that EMP-1 expression may contribute to the development and progress of NSCLC by activating PI3K/AKT pathway.
引用
收藏
页码:834 / 838
页数:5
相关论文
共 50 条
  • [1] EMP-1 Promotes Tumorigenesis of NSCLC through PI3K/AKT Pathway
    来森艳
    王桂华
    曹小年
    李兆明
    胡俊波
    王晶
    Current Medical Science, 2012, (06) : 834 - 838
  • [2] EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway
    Senyan Lai
    Guihua Wang
    Xiaonian Cao
    Zhaoming Li
    Junbo Hu
    Jing Wang
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32 : 834 - 838
  • [3] PGAM5 promotes tumorigenesis of gastric cancer cells through PI3K/AKT pathway
    Meng, Lei
    Hu, Pibo
    Xu, Aman
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 244
  • [4] SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/Akt signaling pathway
    Ai, Yiguo
    Wan, Changhong
    Chen, Zijian
    Wang, Yansheng
    Zhao, Wen
    Huang, Weizhe
    JOURNAL OF BIOSCIENCES, 2024, 49 (02)
  • [5] GRSF1 promotes tumorigenesis and EMT-mediated metastasis through PI3K/AKT pathway in gastric cancer
    Wang, Baohua
    Wang, Lili
    Lu, Yixun
    Liang, Wenquan
    Gao, Yunhe
    Xi, Hongqing
    Chen, Lin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 555 : 61 - 66
  • [6] Strictosamide promotes wound healing through activation of the PI3K/AKT pathway
    Ming, Gu-xu
    Liu, Jun-yan
    Wu, Yu-huang
    Li, Li-yan
    Ma, Xin-yue
    Liu, Pei
    Pan, Yi-peng
    He, Xiao-ning
    Li, Yong-hui
    HELIYON, 2024, 10 (09)
  • [7] PTEN can suppress NSCLC invasion through PI3K/AKT/NFkB pathway
    Akca, H.
    Demiray, A.
    EJC SUPPLEMENTS, 2010, 8 (05): : 142 - 142
  • [8] PI3K pathway in NSCLC
    Martinez-Marti, Alex
    Felip, Enriqueta
    FRONTIERS IN ONCOLOGY, 2012, 1
  • [9] PKIB promotes cell proliferation and the invasion-metastasis cascade through the PI3K/Akt pathway in NSCLC cells
    Dou, Penghui
    Zhang, Danfeng
    Cheng, Zhuoxin
    Zhou, Gang
    Zhang, Linyou
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (17) : 1911 - 1918
  • [10] NPTX1 promotes tumorigenesis of glioma through augmentation of IRS-1/PI3K/AKT signaling
    Huo, Leiming
    Kong, Wentao
    Zheng, Maohua
    Zhang, Yonghong
    Xu, Jiguang
    Yang, Gang
    Guan, Quanlin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (02): : 1649 - 1657